Leukemia Survivorship Follow-Up Questions

Leukemia is not one disease, and follow-up is not one plan. Three of them come up most often here. They are acute myeloid leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia. Each leaves very different long-term questions.

This page draws on the NCI summaries for all three. They are listed at the end. Start by asking which leukemia you had. Then ask which treatments you received.

For chronic myeloid leukemia, treatment is usually a tyrosine kinase inhibitor. It is a pill taken every day. NCI's patient summary lists asciminib, imatinib, dasatinib, nilotinib and bosutinib. Its clinician summary also covers ponatinib.

Cost is part of this conversation, and NCI says so in the clinician version of the same summary. It puts asciminib at 260,000 dollars a year in 2024. It puts imatinib at 500 dollars a year. NCI calls that gap financial toxicity. It adds that the price of the other drugs in the class may fall. Dasatinib is already available as a generic. NCI notes that nilotinib, bosutinib and ponatinib were expected to be released as generics in 2027.

Ask what your drug costs you, not just what it costs.

Sometimes. NCI's clinician summary is careful here. It says the data are insufficient to recommend that everyone stop. That holds even for people with a deep or complete molecular response.

If you do stop, monitoring is required. NCI says follow-up should happen at least every three months at first. It also notes that the precise interval is not well defined. And it warns that relapses have been seen even after two to three years.

It also describes a withdrawal syndrome of muscle and joint pain after stopping.

Graft-versus-host disease is the long shadow of an allogeneic transplant. That is a transplant using cells from a donor. Ask which organs yours affects. Ask who manages it.

Ask, too, about your risk of another blood cancer later. NCI's acute myeloid leukemia summary discusses myelodysplastic syndrome. It also discusses disease caused by earlier treatment.

In chronic lymphocytic leukemia, infections are partly caused by low antibody levels. NCI's clinician summary describes a randomized study of immunoglobulin given into a vein. It produced significantly fewer bacterial infections. It also significantly delayed the first one.

NCI is honest about the limits. There was no effect on survival. Routine long-term use is expensive. And benefit beyond a year is unproven. NCI names herpes zoster, or shingles, as a frequent viral infection in this group.

• Which leukemia did I have, and which drugs did I receive?
• If I take a daily pill, what is monitored and how often?
• Am I a candidate for stopping, and what would monitoring look like?
• What does my most recent molecular test show?
• After my transplant, who manages graft-versus-host disease?
• Should my antibody level be checked?
• What is my risk of a second cancer, and does it change my screening?

Ask for a written care plan. Ask which doctor owns each item on it.

Cancer Staging and Biomarker Testing explain the terms that show up in leukemia follow-up notes. Clinical Trial vs Standard Treatment, Palliative Care, and Questions to Ask Your Doctor cover what to raise at a leukemia survivorship visit.

These questions were drawn from current patient guidance for leukemia:

• NCI PDQ — Acute Myeloid Leukemia Treatment (Patient Version)
• NCI PDQ — Chronic Lymphocytic Leukemia Treatment (Patient Version)
• NCI PDQ — Chronic Myelogenous Leukemia Treatment (Patient Version)
• NCI PDQ — Chronic Myelogenous Leukemia Treatment (Health Professional Version)
• NCI PDQ — Chronic Lymphocytic Leukemia Treatment (Health Professional Version)